Research & Development
Quest Diagnostics expands HPV self-collection screening option
2 April 2025 - Diagnostic information services provider Quest Diagnostics (NYSE: DGX) has introduced a human papillomavirus (HPV) self-collection solution for cervical cancer screening, allowing physi...
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
2 April 2025 - Nasal photodisinfection system provider Ondine Biomedical Inc (LON: OBI) on Wednesday announced successful results from the first NHS deployment of its Steriwave nasal decolonisation te...
GRIN Therapeutics' radiprodil granted Priority Medicine designation in Europe
2 April 2025 - GRIN Therapeutics Inc, a developer of therapies to treat serious neurodevelopmental disorders, announced on Tuesday that it has received Priority Medicine (PRIME) designation for radipr...
Yingli Pharma's linperlisib Phase 3 registration study approved by US FDA
2 April 2025 - Chinese clinical stage biotechnology company Shanghai Yingli Pharmaceutical Co Ltd (Yingli Pharma) announced on Tuesday that it has received approval from the US Food and Drug Administr...
Organon acquires US rights to TOFIDENCE from Biogen
1 April 2025 - Healthcare company Organon (NYSE:OGN) announced on Tuesday that it has acquired the US regulatory and commercial rights to TOFIDENCE, a biosimilar to ACTEMRA, from biotechnology company...
Oncopeptides secures FDA approval to resume OPD5 clinical development
1 April 2025 - Oncopeptides AB (STO:ONCO), a Swedish biotech company focused on difficult-to-treat cancers, announced on Tuesday that the US Food and Drug Administration (FDA) has lifted the clinical ...